The New York-Presbyterian and Columbia University Medical Center (CUMC) is welcoming Dr. Pawel Muranski as its new director of cellular immunotherapy at the Good Manufacturing Practices (GMP) cell production lab and assistant director of transfusion medicine and cellular therapy, the hospital said in a release.
“We’re thrilled to have Dr. Muranski joining us to continue his innovative work,” Dr. Gary Schwartz, chief of the division of hematology/oncology at New York-Presbyterian/CUMC, said in the release. “His approach to T-cell based therapy holds so much potential and could revolutionize care for cancer patients, transplant patients and others.”
Muranski is a hematologist and specializes in bone marrow transplantation and developing adoptive T cell therapies, New York-Presbyterian said in the release. In his new position, he will be working with fellow hematologist Prakash Satwani on a new chimeric antigen receptor (CAR) T cell initiative.
“Despite recent spectacular advances in the field of cancer immunotherapy, very few institutions have GMP laboratories with the capacity to grow and manipulate T cells,” Muranski said in the release. “New York-Presbyterian and Columbia University Medical Center are now positioned to become leaders in cutting-edge cellular immunotherapies. I’m excited to work with the team here on developing a comprehensive program that brings these innovative treatments to our patients.”
